Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 1

Conditions

Prostatic Neoplasms 3Neoplasms 3Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasms × satraplatin × Clear all
NCT00313456 2012-05-10

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Agennix

Phase 1 Terminated
25 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Agennix

Phase 1 Terminated
28 enrolled
Tumor-Agnostic

Neoplasms

NCT00329329 2012-03-23

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Agennix

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡